Trial reportTopics in spinal cord injury rehabilitation2025
Efficacy of Vitamin D3 Supplementation in Elevating Circulating 25(OH)D Concentration in Individuals With Chronic Spinal Cord Injury (VitD-SCI): Evidence From a Randomized, Double-Blind, Placebo-Controlled Trial.
Trial report in Topics in spinal cord injury rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Individuals with spinal cord injury (SCI) are at increased risk for insufficient 25(OH)D levels and associated adverse health outcomes, highlighting the need for vitamin D supplementation. However, the optimal dosing strategy for vitamin D supplementation in this population remains unclear. Objectives: To evaluate the efficacy of medium-dose (MD) and high-dose (HD) vitamin D3 supplementation in raising 25(OH)D levels above the sufficiency threshold of 75 nmol/L in individuals with SCI. Methods: A 12-month randomized, double-blind, placebo-controlled, superiority clinical trial was conducted in 42 individuals living with SCI for at least 3 years and who had insufficient 25(OH)D levels at baseline. Participants (7 female, 35 male; age 48 ± 10 years; 32 with paraplegia, 10 with tetraplegia) were randomly assigned to the placebo, MD intervention (24,000 IU D3 once every 4 weeks), or HD intervention (24,000 IU D3 once every 2 weeks) group. Baseline 25(OH)D levels (43 ± 16 nmol/L) did not differ between intervention groups ( Results: Supplementation was well tolerated, and 25(OH)D levels remained well below the excess threshold. A dose-response effect on 25(OH)D levels was observed [ Conclusion: Vitamin D3 supplementation effectively increased 25(OH)D concentration to sufficient levels in participants with specific characteristics. Higher supplementation doses are needed to successfully increase 25(OH)D levels in all individuals with chronic SCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.